| Abstract | The safety and efficacy of auranofin in the long-term treatment of children with juvenile rheumatoid arthritis was investigated in an open study of 14 patients. Twelve patients completed at least 12 months of treatment, and 7 patients completed 36 months of treatment. Classic parameters of disease activity showed improvement over baseline values after 6 months of treatment, and laboratory indices remained stable or improved throughout the study. Auranofin was well tolerated; the frequency of adverse effects was lower in these patients than has been previously reported in either adults or children whose arthritis has been treated with injectable gold. |
| Authors | R Marcolongo, A Mathieu, R Pala, N Giordano, A Fioravanti, R Panzarasa
(Affiliation: Institute of Rheumatology, University of Siena, Italy.)
|
| Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 31
Issue 8
Pg. 979-83
(Aug 1988)
ISSN: 0004-3591 UNITED STATES |
| PMID | 3044374
(Publication Type: Clinical Trial, Journal Article)
|
| Chemical References |
|
| Topics |
- Adolescent
- Arthritis, Juvenile Rheumatoid
(drug therapy)
- Auranofin
(adverse effects, therapeutic use)
- Child
- Clinical Trials as Topic
- Diarrhea
(chemically induced)
- Female
- Humans
- Male
- Pruritus
(chemically induced)
- Time Factors
|
